This collaboration follows a $2.4 million contract awarded by the US Department of Energy (DoE) to OPT as part of US Secretary of Energy Steven Chu’s initiatives announced in September 2010 to promote the development of renewable marine energy. Cool Video's I hope to see these along most shore lines http://www.oceanpowertechnologies.com/images/banner3.jpg
Ocean Power Technologies, Inc. (Nasdaq: OPTT) is a pioneer in wave energy technology that harnesses ocean wave resources to generate reliable, clean and environmentally-beneficial electricity. OPT has a strong track record in the advancement of wave energy, and participates in an estimated $150 billion annual power generation equipment market. OPT’s proprietary PowerBuoy® system is based on modular, ocean-going buoys that capture and convert predictable wave energy into clean electricity. The Company is widely recognized as a leading developer of on-grid and autonomous wave energy generation systems, benefiting from 15 years of in-ocean experience. OPT is headquartered in Pennington, New Jersey with an office in Warwick, UK. More information can be found at http://bit.ly/od9flA
Friday, October 7, 2011
Ocean Power Technologies and Lockheed Martin to Collaborate on Utility Scale PowerBuoy for Oregon Wave Power Project
See this Amp at http://amplify.com/u/a1ebwz
Sunday, October 2, 2011
Onko-Sure : The Colorectal Cancer Monitoring Blood Test Helps Determine the Effectiveness of your Post-Surgery Therapy and Treatments.
Radient Pharmaceuticals Corporation, a pharmaceutical company, engages in the research, development, manufacture, and marketing of diagnostic and skin care products. It offers ONKO-SURE, a proprietary in-vitro diagnostic cancer test, which is used for the detection and/or monitoring of lung, breast, stomach, liver, colon, rectal, ovarian, esophageal, cervical, trophoblastic, thyroid, malignant lymphoma, and pancreatic cancers. The company also has interests in the Combined Immunogene Therapy, a cancer vaccine therapy technology, which is used to build the body’s immune system and destroy cancer cells. In addition, it provides Elleuxe brand of anti-aging skin care products, including hydrating firming cream, renergie hydrating cleanser, intense hydrating cleanser, visable renewing hydrating softener, and smoothing renewing eye moisturizer. The company sells its products through distributors to hospitals, clinical laboratories, clinics, and other health care organizations primarily in the United States, Canada, Chile, Europe, India, Korea, Taiwan, and Vietnam. It has a collaborative agreement with the Mayo Clinic. The company was formerly known as AMDL, Inc. and changed its name to Radient Pharmaceuticals Corporation in September 2009 to reflect its new corporate direction and branding statements. Radient Pharmaceuticals Corporation was founded in 1988 and is headquartered in Tustin, California. RXPC - Investors Social Network
Colorectal Cancer
Colorectal cancer, commonly known as bowel cancer, is a cancer caused by uncontrolled cell growth (neoplasia), in the colon, rectum, or vermiform appendix.[citation needed] Colorectal Cancer is clinically distinct from anal cancer, which affects the anus.
Colorectal cancers start in the lining of the bowel. If left untreated, it can grow into the muscle layers underneath, and then through the bowel wall. Most begin as a small growth on the bowel wall: a colorectal polyp or adenoma. These mushroom-shaped growths are usually benign, but some develop into cancer over time. Localized bowel cancer is usually diagnosed through colonoscopy.
Invasive cancers that are confined within the wall of the colon (TNM stages I and II) are often curable with surgery, For example, in England over 90% of patients diagnosed at this stage will survive the disease beyond 5 years. However, if left untreated, the cancer can spread to regional lymph nodes (stage III). In England, around 48% of patients diagnosed at this stage survive the disease beyond five years. Cancer that has spread widely around the body (stage IV) is usually not curable; approximately 7% of patients in England diagnosed at this stage survive beyond five years.
Colorectal Cancer is the third most commonly diagnosed cancer in the world, but it is more common in developed countries. Around 60% of cases were diagnosed in the developed world. GLOBOCAN estimated that, in 2008, 1.24 million new cases of colorectal cancer were clinically diagnosed, and that this type of cancer killed 610,000 people. (Taken From Wikipedia Colorectal Cancer )
Onko-Sure® Overview
How Onko-Sure® Works: While the production of Fibrin and Fibrinogen Degradation Products (FDP) is restricted in healthy individuals, FDP are over produced by cancer cells, which release proteolytic enzymes such as plasmin and thrombin. Current assays for FDP usually measure a specific FDP component, such as D-dimer, as a representative of this group; whereas the Onko-Sure® test detects the full complement of FDP. Onko-Sure® acts as a “barometer for cancer” by simultaneously measuring the multiple FDP species that may be underestimated by other tests.
Assay Description: Standard sandwich-type Enzyme-Linked ImmunoSorbent Assay (ELISA). Antigen is captured from human serum samples by an affinity-purified rabbit anti-DR-70® (FDP) antibody that is immobilized in the wells of a standard 96-well assay plate. After appropriate washing, the antigen captured from the serum sample is complexed by a peroxidase-labeled detection antibody to form an immuno-sandwich. The bound enzyme conjugate is quantitatively measured with TMB substrate. Immediately after stopping the enzymatic reaction, the absorbance of the solution is read at 450 nm.
Lung Cancer
Lung cancer is the leading cause of death due to cancer in Canada and on average, 450 Canadians are diagnosed with lung cancer every week.1 It is expected that One in 11 men and one in 16 women will develop lung cancer during his/her lifetime, and one in 13 men and one in 18 women will die from it.1
Based on the SEER Cancer Statistics Review in the period of 1975-2007, the distribution of lung cancers based on histology included: non-small cell lung cancer (NSCLC) (85-90%), small-cell lung cancer (SCLC) (10-15%), sarcoma (0.2%), and other types of lung cancer including bronchial carnoids and cancer of supporting lung tissue (0.1%). Non-small cell lung cancers include: squamous and transitional cell lung carcinomas (19.8%), lung adenocarcinoma (37.5%), and large cell carcinomas (3.3%).
While trends indicate a slight decrease in the incidence of lung cancer in men, there has been an increase in the number of lung cancer cases in women. NSCLC is a common cancer with an approximately 85% death rate and the only chance of a cure for these patients is in the early stages that surgery or chemoradiotherapy can be performed. In general, most lung cancers are diagnosed in late stages, due in part to lack of effective screening procedures. For lung cancer, early detection and/or identification of recurrence with prompt treatment can lead to a better survival rate and quality of life for the patients.
Lung Cancer Diagnosis
Upon learning of a patient’s symptoms, a healthcare provider often formulates a list of possible diagnoses and questions the patient with regard to symptoms, medical and surgical history, smoking, work history, life style, overall health and medications. This is generally followed by a chest X-ray to determine the cause of the respiratory symptoms. In the majority of the patient, a magnetic resonance imaging (MRI) or computed tomography scan (CT scan) of the chest further defines the problem. However, none of these imaging techniques are confirmatory and the only way to confirm lung cancer is histological assessment of the cells or tissue taken by semi-invasive or invasive techniques. Sputum testing may be performed, where cells in the sputum can be examined to see if they are cancerous. Following treatment, patients often undergo regular check-ups, including physical exams, blood tests, chest X-rays, CT scans and bronchoscopy to evaluate the treatment’s efficacy and to monitor for potential lung cancer recurrence.
Imaging techniques can only monitor the macroscopic changes of the tumor mass and often the tumor size changes are detected only after several cycles of therapy.3-5 On the other hand, tumor markers can reflect the activity and metabolism of the cancer cells and can be evaluated as predictive factors either alone or in combination with other histopathological, biochemical and clinical variables.6
Tumor Markers for Lung Cancer
Several biological tumor markers have been tested for lung cancer including: Carcinoembryonic Antigen (CEA), Cytokeratin 19 Fragment Antigen 21-1 (CYFRA21-1), Neuron Specific Enolase (NSE) and Tumor Pyruvate Kinase (TU M2-PK). The blood tests available to determine the concentration of these markers have low sensitivity and are of limited use for lung cancer diagnosis.7 The use of TU M2-PK has been under investigation and has a potential for clinical oncopulmonology, however, because of its low specificity, further studies are needed for its use in NSCLC patients.7
DR-70 is the only other available tumor marker cleared by Health Canada for the detection and treatment and/or recurrence monitoring of lung cancer. Onko-Sure® is a simple, non-invasive, regulatory-approved in vitro diagnostic (IVD) blood test used for the detection of lung cancer and monitoring changes in the level of the marker in response to treatment. It was cleared by Health Canada in 1998. It is an ELISA-based assay that measures the accumulation of Fibrin/Fibrinogen Degradation Products (FDP) in the serum using a polyclonal antibody against the DR-70 tumor marker. The use of this tumor marker can result in possible increased effectiveness in the clinical evaluation of surgical resections in lung cancer patients and also in monitoring of recurrence of lung cancer during the 5-year window post-treatment in lung cancer survivors. In addition, the expected reduction in non-essential invasive diagnostics can lead to benefits for both the individual patient and the healthcare system. Onko-Sure Web SiteSaturday, September 24, 2011
ONTC News Onteco Corporation President Releases Letter to Shareholders, ONTC NexSense Technology
NexPhase Lighting, Inc. continues to make steady progress toward the development of escalating sales revenue. Also important, it continues to draw Lighting Industry top-of-mind awareness for its state-of-the-art, patented technology, even to the extent that some major lighting manufacturers are interested in using our technology in their own LED products, or having us build private label product for them. Clearly, it is in our interest to pursue such opportunities since they allow us to rapidly broaden our market footprint. It is worth noting that LED today is less than 5% of the commercial lighting market, but is forecasted to represent over 50% within a few years. The situation is akin to what a "disruptive technological change" did to the computer industry in the 1980's – a change similar in impact in terms of large across-the-board end-user cost reductions and accelerated efficiencies. We believe NexPhase is at the forefront of such technologies, while it continues to develop its new, ever-expanding product portfolio.
NexSense Technology
ONTC - EquityGroups Investors Social Network
NexSense Technology
NexPhase Lighting uses only the highest quality products in our fixtures. This gives us the ability to provide our customers with a six year or 50,000 hour warranty on our fixtures. From the use of Cree LEDs to our attention to photo-metrics and thermal management, you get only the highest quality, most reliable products from NexPhase Lighting!
Our patent pending “NexSense” technology gives our customers an additional edge in lighting management and in our customer’s Return on Investment (ROI). Incorporated into many of our fixture designs you’ll find advanced sensory features that expand your energy savings beyond just the use of energy saving LEDs. These features include the following:
PROXIMITY SENSING – The most energy saving light fixture available is one that is not on. Building on this, the NexPhase Proximity Sensor monitors movement within a given space and either dims or shuts the lights off if no movement have been sensed within a given period of time (configurable by the user).
AMBIENT LIGHT SENSING – This sensor takes advantage of the Sun free light (energy). Once the occupant of an office sets the light level they like within their space, this sensor monitors the light level throughout the day. If more light comes into the office as the sun rises, the sensing system reduces the amount of light being given off by the fixture to ensure the light level within the space remains the same. The reverse is also true. If storm clouds move in and block the sunlight that was previously coming into the space, the sensing system increases the amount of light from the fixture (up to the maximum output).
Our fixtures can be controlled through a variety of means. Permissions and the types of controls authorized are assigned during set-up. Fixtures, or groups of fixtures can be controlled via a hand-held remote control, through any smart phone (i.e. iPhone), or via the computer.
Our fixtures are intelligent. They incorporate a MESH Networking technology which allows the fixtures to communicate with each other, wirelessly. The set-up and management of our fixtures allow from the combining of multiple fixtures into a given group… Specific offices, hallways, stairwells, conference rooms, etc.
NexSense Technology
NexSense Technology
ONTC - EquityGroups Investors Social Network
Thursday, September 22, 2011
WTWO W2 Energy Builds Next Generation Compressed Air Engine
Compressed air engine
2 Cool Videos : Mike McLaren, the President and CEO of W2 Energy, recently returned from Tucson, Arizona, where he spent 3 days commissioning the first iteration of the AzRISE CAES system. Since his return to Guelph, Ontario, he has been working with W2 Staff to build the next generation AirRocket to mate with the AzRISE system. Once tested at AzRISE the entire CAES system will be installed and tested at the Tucson Electric Power site featuring Solon solar technology.
http://bit.ly/mTvj9d
W2 Energy is currently completing a 65 horsepower version of the AirRocket to be installed in a high-end composite motorcycle which is being built in a joint venture with one of the major custom motorcycle builders in the United States.
"The AirRocket engine development is driving much of our new technology," says Mike McLaren. "Whether as a power plant for vehicles or as part of an energy storage and recovery system, we think the AirRocket will dramatically add to W2 Energy's bottom line." compressed air engine
See this Amp at http://amplify.com/u/a1dbbq
Monday, September 19, 2011
India's Improving Broadband Usage Boosts Popularity in Rediff and Sify
India's internet sector (CEO Video!) is continuing to grow at a steady pace this year. http://bit.ly/qCpdSC A recent report from McKinsey says that the Internet contributed 5 percent to India's GDP growth in the past five years, higher than the average 3 percent for "BRIC" (Brazil, Russia, India and China) economies but much lower than the US (15 percent). The Bedford Report examines the outlook for companies in India's Internet Sector and provides investment research on Rediff.com India Ltd. (NASDAQ: REDF) and Sify Technologies Limited (NASDAQ: SIFY) REDF message board Indias Improving Broadband Usage Boosts Popularity in Rediff and Sify
See this Amp at http://amplify.com/u/a1d49i
Friday, September 16, 2011
GTX is focused on GPS tracking and monitoring technologies that are easy to use and offer 24/7 global tracking capability
While their products can be found in commercial shipping applications, the company is a leader in helping families keep at risk members safe. Patrick Bertagna, CEO of GTX Corp, described the reason behind the company’s development of an innovative category of personal location-based services as “keeping you connected to whom and what matters most.”
He added, “The GPS Tracking app is the simplest way to stay connected to a child, parent, friend or business associate, quickly and accurately from a Smartphone or internet ready device like the iPad, iPod or Android tablet, allowing users to locate people, instantly with one simple touch of a button. We also offer it at a price everyone can afford without compromising privacy.”
http://bit.ly/njQwKI
See this Amp at http://amplify.com/u/a1cyq6
Wednesday, September 14, 2011
AeroVironment Receives $16 Million Order for Raven Unmanned Aircraft Systems Contractor Logistics Support
Very cool video of the product in action! The Raven unmanned aircraft is a 4.2-pound, backpackable, hand-launched sensor platform that provides day and night, real-time video imagery for "over the hill" and "around the corner" reconnaissance, surveillance and target acquisition in support of tactical units. U.S. armed forces use Raven systems extensively for missions such as base security, route reconnaissance, mission planning and force protection. Each Raven system typically consists of three aircraft, two ground control stations and spares. http://bit.ly/pdg7Fw
See this Amp at http://amplify.com/u/a1cuhf
Subscribe to:
Posts (Atom)